3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience. (September 2015) - Cadranel, J.; Cortot, A.; Lena, H.; Mennecier, B.; Do, P.; Dansin, E.; Mazieres, J.; Chouaid, C.; Perol, M.; Barlesi, F.